Business Biocon share price shoots up on Q1 numbers and biologics business Updated : July 27, 2018 04:11 PM IST Biocon's contract research and manufacturing arm, Syngene International, reported a 39 percent YoY growth. Biocon–Mylan received approval for two biosimilar drugs pegfilgrastim and trastuzumab in the past seven months, marking their entry in to the coveted US biosimilar market. Subscribe to Moneycontrol PRO at just Rs.33/- per month for the first year. Use code SUPERPRO. Limited period offer. Available on Web and Android.